Stabilisation of cardiopulmonary function in newborns with congenital diaphragmatic hernia using lung function parameters and hemodynamic management

Klin Padiatr. 2012 Jul;224(4):e1-e10. doi: 10.1055/s-0031-1299731. Epub 2012 Jul 10.

Abstract

Objective: Evaluation of lung function parameters and additional use of prostaglandin E1 (PGE1) for the stabilisation of cardiopulmonary function in patients with congenital diaphragmatic hernia (CDH) and pulmonary hypertension (PHT).

Design: Observational study.

Patients: Between 2007 and 2009 8 patients with CDH have been treated in our pediatric intensive care unit (gestational age 34 + 0 - 40 + 4 weeks, birth weight 2 160-3 840 g). All patients required respiratory support. Gentle mechanical ventilation adapted to the degree of pulmonary hypoplasia based on serially measurements of lung function parameters to find appropriate ventilator settings has been performed.

Main results: Functional residual capacity (FRC) and compliance of the respiratory system in all patients were markedly reduced. A FRC between 9.3-10.6 ml/kg and compliance between 1.1-1.8 ml/kPa/kg indicated pronounced hypoplasia of the lungs. Doppler flow patterns through the arterial duct were classified into left-to-right, right-to-left and bidirectional shunting and correlated to the degree of PHT. The additional use of PGE1 to reopen the arterial duct and to stabilize right ventricular function led to an amelioration of severe PHT and preoperative stabilisation in 2 newborns with pronounced pulmonary hypoplasia. All patients underwent successful surgery, and did not show any complications after 2 years follow-up.

Conclusion: Measurements of lung function parameters and adaptation of mechanical ventilation to the degree of pulmonary hypoplasia and additional therapy with PGE1 may help to improve the outcome in CDH patients.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Abnormalities, Multiple / physiopathology*
  • Abnormalities, Multiple / therapy*
  • Algorithms
  • Alprostadil / administration & dosage*
  • Combined Modality Therapy
  • Ductus Arteriosus, Patent / physiopathology
  • Ductus Arteriosus, Patent / therapy
  • Echocardiography, Doppler
  • Functional Residual Capacity / physiology
  • Heart Failure / physiopathology*
  • Heart Failure / therapy*
  • Hemodynamics / physiology
  • Hernia, Diaphragmatic / physiopathology
  • Hernia, Diaphragmatic / therapy
  • Hernias, Diaphragmatic, Congenital*
  • Humans
  • Hypertension, Pulmonary / physiopathology*
  • Hypertension, Pulmonary / therapy*
  • Infant, Newborn
  • Infant, Premature, Diseases / physiopathology*
  • Infant, Premature, Diseases / therapy*
  • Intensive Care Units, Neonatal
  • Lung / abnormalities
  • Lung / physiopathology
  • Lung Diseases / physiopathology*
  • Lung Diseases / therapy*
  • Oxygen / blood
  • Respiration, Artificial*
  • Respiratory Function Tests*
  • Ventricular Dysfunction, Right / physiopathology*
  • Ventricular Dysfunction, Right / therapy*

Substances

  • Alprostadil
  • Oxygen

Supplementary concepts

  • Lung agenesis